TuHURA Biosciences (NASDAQ:HURA) Shares Down 2.6% – Here’s What Happened

TuHURA Biosciences (NASDAQ:HURA)’s share price fell 2.6% during trading on Thursday . The company traded as low as $4.66 and last traded at $4.92. 320,091 shares traded hands during mid-day trading, an increase of 42% from the average session volume of 224,917 shares. The stock had previously closed at $5.05.

Analysts Set New Price Targets

A number of research firms recently commented on HURA. Rodman & Renshaw began coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Finally, Maxim Group began coverage on TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective on the stock.

TuHURA Biosciences Price Performance

The business’s 50 day moving average is $4.75.

Hedge Funds Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences (NASDAQ:HURA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned 0.15% of TuHURA Biosciences as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.